



FOR IMMEDIATE RELEASE

CONTACT:
Ron Connolly
Frontage
610.232.0100
rconnolly@frontagelab.com

Frontage Launches DMPK Services with Experienced Research Team

(Exton, PA; April 15, 2010) – [Frontage Laboratories, Inc. \("Frontage"\)](#), a leading high quality provider of preclinical, clinical, bioanalytical, chemistry, manufacturing and control (CMC) analytical, synthesis and formulation services to global pharmaceutical companies, announces the launch of its Drug Metabolism and Pharmacokinetics (DMPK) unit and hiring of experienced leadership for this key service area.

Dr. Abdul Mutlib has been appointed as Vice President of DMPK Services for Frontage. With over 20 years of drug metabolism research experience, Dr. Mutlib has hired a strong operations team that will provide quality and cost effective *in-vitro* and *in-vivo* DMPK study execution for Frontage clients. Dr. Mutlib has extensive experience and expertise in drug development and metabolism studies, having contributed to over 60 publications and patents. He is currently serving as a reviewer/editor for several drug metabolism-related journals including *Chemical Research in Toxicology* (an ACS publication), *Drug Metabolism and Disposition*, and *Drug Metabolism Letters*. He is a thought leader in studies of Metabolites in Safety Toxicology (MIST), metabolite characterization, reactive metabolites, and metabolism-mediated toxicities. Dr. Mutlib has led DMPK research teams at organizations such as DuPont-Merck, Pfizer, Hoechst-Roussel (Aventis), and Wyeth Pharmaceuticals. He holds a Ph.D. in Pharmaceutical Chemistry from University of Sydney, with postdoctoral experiences at the University of British Columbia and University of Washington.

Other scientific leaders joining Dr. Mutlib in Frontage's DMPK team include the following:

- Dr. Jack Wang, Assistant Vice President: Dr. Wang has more than 24 years of experience in structure elucidation, mass spectrometry, drug metabolism and analytical chemistry. Jack has contributed to more than 30 technical papers, patents and book

-more-

chapters related to this field of research and earned his Ph.D. at Beijing University with post-doctoral experience at the University of Toronto. Dr. Wang has led drug metabolism research teams at Wyeth and analytical research teams at Apotex, the Medical University of South Carolina and University of Toronto.

- Dr. Li Shen, Associate Director: Dr. Shen brings more than 10 years of experience in development drug metabolism. Her experience ranges from mass balance studies, metabolite profiling, enzyme ID and kinetics, drug-drug interaction, enzyme induction and enzyme inhibition studies. Dr. Shen is an expert in DMPK studies to support projects from pre-IND through post-registration.
- Jim Burleigh, Lab Manager: Mr. Burleigh has over 25 years of experience in conducting ADME studies in laboratory animals. Jim has held various positions in this field with Parke-Davis, Warner Lambert, and Pfizer. He will be heading Frontage's vivarium activities in USA.
- Dr. Seonghee Park, Senior Scientist: Dr. Park brings many years of experience in sandwich-cultured hepatocytes, transporters and Caco-2/MDCK permeability assays.
- Peter Liu, MS, Associate Director: Mr. Liu has more than 20 years experience in bioanalysis. He has accumulated experience in developing, validating and implementing complex LC/MS/MS assays for the quantitation of drugs in biological matrices in GLP and non-GLP environments.

As a result of these key hires, Frontage is able to immediately offer Drug Metabolism and Pharmacokinetic (DMPK) services for drug discovery and development efforts to our pharmaceutical clients. *In-vitro* studies, such as CYP inhibition studies, metabolic profiling and identification, metabolic stability using microsomes and hepatocytes, reaction phenotyping, MDCK permeability studies, plasma/blood partitioning studies and protein binding, plus support for in-life studies. Frontage also offers organic synthesis support to create metabolite reference standards and stable-labeled compounds. Over the next few months, Frontage intends to add in-life mass balance study services in USA and China.

“The launch of our DMPK services have come at an excellent time, as we see increasing demand for more efficient discovery PK and drug metabolism understanding as compounds move into preclinical and clinical research. With a team that has years of experience working together in the pharmaceutical industry, Frontage is in a position to offer excellent value and

quality execution for studies to be conducted by our new DMPK team.,” stated President and Chief Executive Officer, Song Li, Ph.D. “Dr. Mutlib and his team have proven track records in the industry and will greatly contribute to the success of our clients’ drug discovery and development programs.”

About Frontage

Frontage is a rapidly expanding global pharmaceutical research and development services company with facilities in the U.S. and China. Frontage provides a broad range of early drug development services to facilitate pharmaceutical discovery, development, preclinical, clinical research, and regulatory consulting to assist Sponsor companies to resolve complex product development issues. The company’s clients include seven of the top ten largest pharmaceutical companies in the world, as well as many other drug development companies and biotechnology firms. Frontage is experienced with developing new chemical entities, generic equivalent products, and supporting research for small and large molecules. For more information, please contact us at sales@frontagelab.com or visit us at www.frontagelab.com.

###